Moderna (MRNA) closed at $196.79 on November 18, 2026, down 4.8% from the previous close, on volume of 6,457,485 shares (30-day average 15,082,652).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 30, 2026 | Diagonal Double Call Spread | 30-Oct-26210 : 222.5 C|06-Nov-26232.5 : 247.5 C | 19,700 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Moderna 600% YTD rally catches cold: What's next amid stock's downtrend?
Seeking Alpha News (Wed, 18-Nov 12:58 PM ET)
Moderna drops marking longest losing streak since 2024
Seeking Alpha News (Wed, 18-Nov 12:47 PM ET)
Alnylam tops healthcare earnings surprise list, ahead of Regeneron and Eli Lilly
Seeking Alpha News (Tue, 17-Nov 6:08 AM ET)
Moderna Amends Credit Agreement, Extends Loan Maturities
TipRanks (Mon, 16-Nov 7:08 PM ET)
TipRanks (Mon, 16-Nov 9:50 AM ET)
Nasdaq gains 2% in a bumpy week for Wall Street; Nvidia loses ~13%
Seeking Alpha News (Fri, 13-Nov 5:14 PM ET)
Moderna Chief Legal Officer Announces Retirement Agreement
TipRanks (Fri, 13-Nov 4:44 PM ET)
Evercore ISI Keeps Their Hold Rating on Moderna (MRNA)
TipRanks (Fri, 13-Nov 3:45 PM ET)
TipRanks (Fri, 13-Nov 12:45 PM ET)
Moderna Advances Updated mRNA Flu Vaccine Study as Investors Watch Pipeline Progress
TipRanks (Fri, 13-Nov 11:32 AM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of November 18, 2026, MRNA stock price declined to $196.79 with 6,457,485 million shares trading.
MRNA has a beta of 0.11, meaning it tends to be less sensitive to market movements. MRNA has a correlation of 0.00 to the broad based SPY ETF.
MRNA has a market cap of $78.04 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $1 billion in Revenue and $.38 earnings per share. This beat revenue expectation by $423 million and exceeded earnings estimates by $1.60.
In the last 3 years, MRNA traded as high as $280.80 and as low as $22.28.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
MRNA has outperformed the market in the last year with a return of +694.8%, while the SPY ETF gained +10.8%. In the last 3 month period, MRNA beat the market returning +205.3%, while SPY returned -5.3%. However, in the most recent 2 weeks MRNA has underperformed the stock market by returning -13.9%, while SPY returned -3.2%.
MRNA support price is $194.16 and resistance is $219.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.